A CAR T-cell therapy called brexucabtagene autoleucel (Tecartus) has been approved by the Food and Drug Administration (FDA) for some patients with mantle cell lymphoma. This is the third CAR-T cell therapy approved by FDA for patients with cancer.
from Cancer Currents: An NCI Cancer Research Blog https://ift.tt/2EdjRdq
from Cancer Currents: An NCI Cancer Research Blog https://ift.tt/2EdjRdq